


Pending Claims for US Serial No 10/023,053


Client Ref. 00399-04  
Atty. Dkt. 1036.003US3

Claims:

1.(Cancelled) A compound selected from the group consisting of



and



5


wherein  $R_1$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

$R_3$  is hydroxy or  $-OCONH_2$ ; and

$R_4$  is hydroxy or carbonyl.

10

2. (Cancelled) The compound of claim 1 having the general structure:




wherein  $R_1$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

$R_3$  is hydroxy or  $-OCONH_2$ ; and  
 $R_4$  is hydroxy or carbonyl.

- 5            3. (Cancelled) The compound of claim 2 wherein  $R_7$  and  $R_8$  are H;  
 $R_1$  is H or F; and  
 $R_4$  is hydroxy or carbonyl.


4. (Cancelled) The compound of claim 1 having the general structure:



- 10            wherein  $R_1$  is selected from the group consisting of halo, haloalkyl and hydroxy;  
 $R_7$  and  $R_8$  are independently selected from the group consisting of H, halo,  
alkyl, haloalkyl and hydroxy; and  
 $R_3$  is hydroxy or  $-OCONH_2$ .

- 15            5. (Cancelled) The compound of claim 4 wherein  $R_7$  and  $R_8$  are H;  
 $R_1$  is F; and  
 $R_3$  is hydroxy or  $-OCONH_2$ .

6. (Cancelled) The compound of claim 1 having the general structure




wherein  $R_1$  is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

$R_3$  is hydroxy or  $-OCONH_2$ .

- 5            7. (Cancelled) The compound of claim 6 wherein  $R_1$  is H; and  
 $R_3$  is  $-OCONH_2$ .

8. (Cancelled) The compound of claim 1 having the general structure




- 10            wherein  $R_1$  and  $R_7$  are independently selected from the group  
consisting of H, halo, haloalkyl and hydroxy; and  
 $R_4$  is hydroxy or carbonyl.


9. (Cancelled) The compound of claim 8 wherein  $R_7$  is H.

- 15            10. (Cancelled) The compound of claim 6 or 9 wherein  $R_1$  is H or F.

11. (Cancelled) A method for treating a patient suffering from a neurological  
disorder, said method comprising the step of administering a composition  
20            comprising a compound selected from the group consisting of



and



wherein  $R_1$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

5  $R_3$  is hydroxy or  $-OCONH_2$ ; and

$R_4$  is hydroxy or carbonyl.


12. (Cancelled) The method of claim 11 wherein the composition is administered orally.

10

13. (Cancelled) The method of claim 12 wherein the unit dosage form of the composition comprises about 0.1 mg/kg to about 1 g/kg of said compound.

14. (Cancelled) The method of claim 13 wherein said compound has the general structure

15



wherein  $R_1$  is selected from the group consisting of H, halo, haloalkyl and hydroxy; and


$R_3$  is hydroxy or  $-OCONH_2$ .

5


15. (Cancelled) The method of claim 14 wherein  $R_1$  is H; and

$R_3$  is  $-OCONH_2$ .

10 16. (Cancelled) A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions, said method comprising the step of administering a composition comprising a compound selected from the group consisting of



and




15

wherein  $R_1$ ,  $R_7$  and  $R_8$  are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

$R_3$  is hydroxy or  $-OCONH_2$ ; and

$R_4$  is hydroxy or carbonyl.

17. (Cancelled) The method of claim 16 wherein said compound has the general structure



wherein R<sub>1</sub> is selected from the group consisting of H, halo, haloalkyl  
5 and hydroxy; and  
R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

18. (Cancelled) The method of claim 17 wherein R<sub>1</sub> is H; and  
R<sub>3</sub> is -OCONH<sub>2</sub>.  
10

19. (Cancelled) The method of claim 16 wherein the localized hypoxic condition is caused by cerebral ischemia.


20. (Cancelled) The method of claim 16 wherein the localized hypoxic  
15 condition is caused by myocardial ischemia.

21. (Cancelled) The method of claim 16 wherein the composition is administered orally.


22. (Cancelled) The method of claim 16 wherein the composition is  
20 administered parenterally.

23. (Cancelled) The method of claim 22 wherein the unit dosage form of the composition comprises about 1.0 mg/kg to about 1 g/kg of said compound and the  
25 composition is administered intravenously.

24. (Cancelled) A pharmaceutical composition comprising a compound selected from the group consisting of




and



wherein  $R_1$ ,  $R_7$  and  $R_8$  are independently selected from the group  
5 consisting of H, halo, alkyl, haloalkyl and hydroxy;  
 $R_3$  is hydroxy or  $-OCONH_2$ ; and  
 $R_4$  is hydroxy or carbonyl, and a pharmaceutically acceptable carrier.

25. (Cancelled) The composition of claim 24 wherein said compound has  
10 the general structure




wherein  $R_1$  is selected from the group consisting of H, halo, haloalkyl  
and hydroxy; and  
 $R_3$  is hydroxy or  $-OCONH_2$ .

26. (Cancelled) The composition of claim 25 wherein  $R_1$  is selected from the group consisting of halo, haloalkyl and hydroxy.

5 27. (Cancelled) The composition of claim 25 wherein  $R_1$  is H; and  
 $R_3$  is  $-OCONH_2$ .

28. (Cancelled) The composition of claim 24 wherein said compound has the general structure




10 wherein  $R_1$  and  $R_7$  are independently selected from the group consisting of H, halo, haloalkyl and hydroxy;  
and  $R_3$  is hydroxy or  $-OCONH_2$ .

15 29. (Cancelled) The composition of claim 28 wherein  $R_7$  is H.

30. (Cancelled) The composition of claim 25, 28 or 29 wherein  $R_1$  is H or F.

31.(NEW) A compound of the formula:



wherein:  $R_2$  is halo; and  $R_3$  is hydroxy or  $-OCONH_2$ .



- 32.(NEW) The compound of claim 31 wherein  $R_2$  is chloro or fluoro.
- 33.(NEW) The compound of claim 31 wherein  $R_2$  is fluoro.
- 5 34.(NEW) The compound of claim 31 wherein  $R_3$  is hydroxy.
- 35.(NEW) The compound of claim 31 wherein  $R_3$  is  $-OCONH_2$ .
- 36.(NEW) The compound of claim 34 wherein  $R_2$  is chloro or fluoro.
- 10 37.(NEW) The compound of claim 34 wherein  $R_2$  is fluoro.
- 38.(NEW) The compound of claim 35 wherein  $R_2$  is chloro or fluoro.
- 15 39.(NEW) The compound of claim 35 wherein  $R_2$  is fluoro.
- 40.(NEW) A composition comprising a compound as described in claim 31, and  
a pharmaceutically acceptable carrier.
- 20 41. (NEW) A composition comprising a compound as described in claim 39, and  
a pharmaceutically acceptable carrier.
- 42.(NEW) A method for treating a patient suffering from a neurological  
disorder, comprising administering to the patient, an effective  
25 amount of a compound as described in claim 31.
- 43.(NEW) A method for treating a patient suffering from tissue damage  
resulting from localized hypoxic conditions comprising

Client Ref. 00399-04  
Atty. Dkt. 1036.003US3

administering to the patient, an effective amount of a compound as described in claim 31.

5           44.(NEW)   A method for treating a patient suffering from a neurological disorder, comprising administering to the patient, an effective amount of a compound as described in claim 39.

10           45.(NEW)   A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions comprising administering to the patient, an effective amount of a compound as described in claim 39.